Analyst Says Viridian's New Thyroid Eye Drug Could Outperform Amgen's Tepezza
William Blair initiated coverage on Viridian Therapeutics Inc. (NASDAQ:VRDN) on Wednesday.
Benzinga ·
Get all your news in one place.
100's of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100's of premium titles. One news app.
SHOCKING: Vrdn | Mind Blowing Facts
These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results
Viridian Therapeutics, Inc. (NASDAQ:VRDN) reported upbeat results for the second quarter on Wednesday.
Benzinga ·
3 Top Small-Cap Tech Picks for Investors This Month
Wall Street believes these three small companies have significant upside potential.
Barchart ·
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Coverage From
Benzinga
Barchart
People
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Organisations
Read news from The Economist, FT, and more,
with one subscription
with one subscription
Topics
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.
100+ trusted global sources.
